HRP20000665B1 - CRYSTALLINE FORMS OF 1S-[1alpha(2S*,3R*), 9alpha]10-DIOXO-N-(2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL)-9-[[(1-ISOQUINOLYL)CARBONYL]-AMINO]OCTAHYDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPIN- 1-CARBOXAMIDE - Google Patents
CRYSTALLINE FORMS OF 1S-[1alpha(2S*,3R*), 9alpha]10-DIOXO-N-(2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL)-9-[[(1-ISOQUINOLYL)CARBONYL]-AMINO]OCTAHYDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPIN- 1-CARBOXAMIDEInfo
- Publication number
- HRP20000665B1 HRP20000665B1 HR20000665A HRP20000665A HRP20000665B1 HR P20000665 B1 HRP20000665 B1 HR P20000665B1 HR 20000665 A HR20000665 A HR 20000665A HR P20000665 A HRP20000665 A HR P20000665A HR P20000665 B1 HRP20000665 B1 HR P20000665B1
- Authority
- HR
- Croatia
- Prior art keywords
- octahydro
- dioxo
- furanyl
- carboxamide
- tetrahydro
- Prior art date
Links
- -1 1-ISOQUINOLYL Chemical class 0.000 title abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- AUHBCNJHXCDLMK-UHFFFAOYSA-N diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=CC=N1 AUHBCNJHXCDLMK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9804367A FR2777279B1 (fr) | 1998-04-08 | 1998-04-08 | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
PCT/FR1999/000799 WO1999052935A1 (fr) | 1998-04-08 | 1999-04-07 | Formes cristallines du 1s-[1alpha (2s*,3r*),9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepine-1- carboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20000665A2 HRP20000665A2 (en) | 2001-08-31 |
HRP20000665B1 true HRP20000665B1 (en) | 2008-01-31 |
Family
ID=9524993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000665A HRP20000665B1 (en) | 1998-04-08 | 2000-10-09 | CRYSTALLINE FORMS OF 1S-[1alpha(2S*,3R*), 9alpha]10-DIOXO-N-(2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL)-9-[[(1-ISOQUINOLYL)CARBONYL]-AMINO]OCTAHYDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPIN- 1-CARBOXAMIDE |
Country Status (38)
Country | Link |
---|---|
US (2) | US6544977B1 (et) |
EP (1) | EP1070083B1 (et) |
JP (1) | JP2002511485A (et) |
KR (1) | KR100582981B1 (et) |
CN (1) | CN1202123C (et) |
AP (1) | AP1734A (et) |
AR (1) | AR018328A1 (et) |
AT (1) | ATE315044T1 (et) |
AU (1) | AU758042B2 (et) |
BG (1) | BG64736B1 (et) |
BR (1) | BR9909549A (et) |
CA (1) | CA2325629C (et) |
CU (1) | CU23055A3 (et) |
CZ (1) | CZ299744B6 (et) |
DE (1) | DE69929315T2 (et) |
DK (1) | DK1070083T3 (et) |
EA (1) | EA002761B1 (et) |
EE (1) | EE04467B1 (et) |
ES (1) | ES2253880T3 (et) |
FR (1) | FR2777279B1 (et) |
GE (1) | GEP20032974B (et) |
HK (1) | HK1038575B (et) |
HR (1) | HRP20000665B1 (et) |
HU (1) | HU227561B1 (et) |
ID (1) | ID26290A (et) |
IL (2) | IL138818A (et) |
ME (1) | ME01627B (et) |
NO (1) | NO327995B1 (et) |
NZ (1) | NZ507199A (et) |
PL (1) | PL197016B1 (et) |
RS (1) | RS49916B (et) |
SI (1) | SI1070083T1 (et) |
SK (1) | SK286267B6 (et) |
TR (1) | TR200002914T2 (et) |
TW (1) | TW522152B (et) |
UA (1) | UA71563C2 (et) |
WO (1) | WO1999052935A1 (et) |
ZA (1) | ZA200005438B (et) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0713951B8 (pt) * | 2006-06-30 | 2021-05-25 | Novartis Ag | derivados de quinazolina, e composição farmacêutica |
AU2014277867B2 (en) * | 2007-12-04 | 2016-11-03 | Arbutus Biopharma Corporation | Targeting lipids |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
-
1998
- 1998-04-08 FR FR9804367A patent/FR2777279B1/fr not_active Expired - Lifetime
-
1999
- 1999-03-15 TW TW088103966A patent/TW522152B/zh not_active IP Right Cessation
- 1999-03-30 AR ARP990101432A patent/AR018328A1/es active IP Right Grant
- 1999-04-07 ID IDW20002015A patent/ID26290A/id unknown
- 1999-04-07 BR BR9909549-1A patent/BR9909549A/pt not_active Application Discontinuation
- 1999-04-07 CA CA2325629A patent/CA2325629C/fr not_active Expired - Fee Related
- 1999-04-07 WO PCT/FR1999/000799 patent/WO1999052935A1/fr active IP Right Grant
- 1999-04-07 AP APAP/P/2000/001939A patent/AP1734A/en active
- 1999-04-07 HU HU0101586A patent/HU227561B1/hu not_active IP Right Cessation
- 1999-04-07 NZ NZ507199A patent/NZ507199A/xx not_active IP Right Cessation
- 1999-04-07 KR KR1020007011159A patent/KR100582981B1/ko not_active IP Right Cessation
- 1999-04-07 SK SK1488-2000A patent/SK286267B6/sk not_active IP Right Cessation
- 1999-04-07 PL PL343350A patent/PL197016B1/pl unknown
- 1999-04-07 EE EEP200000586A patent/EE04467B1/et unknown
- 1999-04-07 RS YUP-608/00A patent/RS49916B/sr unknown
- 1999-04-07 JP JP2000543491A patent/JP2002511485A/ja active Pending
- 1999-04-07 DE DE69929315T patent/DE69929315T2/de not_active Expired - Lifetime
- 1999-04-07 EP EP99911890A patent/EP1070083B1/fr not_active Expired - Lifetime
- 1999-04-07 TR TR2000/02914T patent/TR200002914T2/xx unknown
- 1999-04-07 EA EA200001047A patent/EA002761B1/ru not_active IP Right Cessation
- 1999-04-07 US US09/647,858 patent/US6544977B1/en not_active Expired - Lifetime
- 1999-04-07 CN CNB998071455A patent/CN1202123C/zh not_active Expired - Fee Related
- 1999-04-07 ES ES99911890T patent/ES2253880T3/es not_active Expired - Lifetime
- 1999-04-07 CU CU20000213A patent/CU23055A3/es unknown
- 1999-04-07 AT AT99911890T patent/ATE315044T1/de active
- 1999-04-07 AU AU30416/99A patent/AU758042B2/en not_active Ceased
- 1999-04-07 GE GEAP19995614A patent/GEP20032974B/en unknown
- 1999-04-07 CZ CZ20003678A patent/CZ299744B6/cs not_active IP Right Cessation
- 1999-04-07 ME MEP-2000-608A patent/ME01627B/me unknown
- 1999-04-07 DK DK99911890T patent/DK1070083T3/da active
- 1999-04-07 SI SI9930877T patent/SI1070083T1/sl unknown
- 1999-07-04 UA UA2000116295A patent/UA71563C2/uk unknown
-
2000
- 2000-10-02 IL IL138818A patent/IL138818A/en not_active IP Right Cessation
- 2000-10-05 ZA ZA200005438A patent/ZA200005438B/en unknown
- 2000-10-06 BG BG104829A patent/BG64736B1/bg unknown
- 2000-10-06 NO NO20005060A patent/NO327995B1/no not_active IP Right Cessation
- 2000-10-09 HR HR20000665A patent/HRP20000665B1/xx not_active IP Right Cessation
-
2002
- 2002-01-07 HK HK02100107.8A patent/HK1038575B/zh not_active IP Right Cessation
- 2002-11-18 US US10/299,242 patent/US6946459B2/en not_active Expired - Lifetime
-
2005
- 2005-04-14 IL IL168047A patent/IL168047A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2131781T3 (es) | Formulacion estable liofilizada que comprende una proteina, equipo de dosificacion. | |
HUP9902136A3 (en) | Novel substituted cyclic amino acid derivatives use as pharmaceutical agents | |
ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
ATE222237T1 (de) | Endothelin-antagonisten | |
ATE201964T1 (de) | Karamellen enthaltend ein süssungsmittel | |
HUP9903823A3 (en) | Use of sibutramine analogues for the preparation of pharmaceutical compositions suitable for lowering lipid levels | |
BG102589A (en) | 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists | |
BR9813817A (pt) | Análogos de hemiasterlina | |
ES2062137T3 (es) | Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea. | |
HRP20000665B1 (en) | CRYSTALLINE FORMS OF 1S-[1alpha(2S*,3R*), 9alpha]10-DIOXO-N-(2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL)-9-[[(1-ISOQUINOLYL)CARBONYL]-AMINO]OCTAHYDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPIN- 1-CARBOXAMIDE | |
BG101849A (en) | Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions | |
NO992298L (no) | Konformasjonsbegrensede LH-RH analoger, anvendelse derav og farmas°ytiske sammensetninger inneholdende disse | |
HUP0100802A2 (hu) | (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanolt tartalmazó új gyógyszerkészítmények | |
ZA916918B (en) | Amino acid analogs as CCK antagonists. | |
ITMI931371A1 (it) | Procedimento per la preparazione dell'erdosteina | |
EP1306366A3 (en) | New dibenzosuberone derivatives | |
SI0888286T1 (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
IL152921A0 (en) | Preparation of [1s-[alpha, 2beta, 3beta, 4alpha(s*)]]-4-[7-[[1-3-chloro-2-thienyl) methyl] propyl] amino]-3h-imidazo[4,5-b]pyridin-3-yl-]-n-ethyl-2, 3 dihydroxycyclopentanecarboxamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
PPPP | Transfer of rights |
Owner name: AVENTIS PHARMA S.A., FR |
|
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170320 Year of fee payment: 19 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180407 |